Recent Winners


+180%
PLX
Alert Price: $0.36
High Price: $1.01
Results: 180% in 40 Days
+157%
OREX
Alert Price: $1.81
High Price: $4.65
Results: 157% in 36 Days
+91%
GBT
Alert Price: $15.85
High Price: $30
Results: 91% in 41 Days
+87%
ARIA
Alert Price: $12.72
High Price: $23.75
Results: 87% in 20 Days
+58%
XGTI
Alert Price: $1.47
High Price: $2.32
Results: 58% in 29 Days
+55%
EXAS
Alert Price: $15.10
High Price: $23.40
Results: 55% in 37 Days
+38%
EDIT
Alert Price: $18.24
High Price: $25.09
Results: 38% in 55 Days
+36%
CYNO
Alert Price: $48.25
High Price: $65.90
Results: 36% in 28 Days
+32%
EBS
Alert Price: $27.22
High Price: $35.88
Results: 32% in 6 Days
+27%
ICHR
Alert Price: $13.40
High Price: $17.04
Results: 27% in 22 Days
+23%
CNAT
Alert Price: $4.43
High Price: $5.45
Results: 23% in 3 Days
+23%
PEIX
Alert Price: $8.30
High Price: $10.25
Results: 23% in 12 Days
+21%
KATE
Alert Price: $15.40
High Price: $18.67
Results: 21% in 11 Days
+20%
REPH
Alert Price: $6.89
High Price: $8.25
Results: 20% in 11 Days
+20%
SN
Alert Price: $11.24
High Price: $13.46
Results: 20% in 15 Days
+16%
CX
Alert Price: $7.97
High Price: $9.30
Results: 16% in 10 Days
+16%
ACAD
Alert Price: $32.03
High Price: $37.09
Results: 16% in 26 Days
+15%
PVG
Alert Price: $7.17
High Price: $8.24
Results: 15% in 6 Days
+12%
OCLR
Alert Price: $8.49
High Price: $9.55
Results: 12% in 7 Days
+12%
ACET
Alert Price: $19.50
High Price: $21.93
Results: 12% in 26 Days
+12%
COW
Alert Price: $20.00
High Price: $22.42
Results: 12% in 26 Days
+11%
PLKI
Alert Price: $70.82
High Price: $79
Results: 11% in 5 Days
+10%
HWKN
Alert Price: $48.15
High Price: $52.90
Results: 10% in 14 Days
+9%
LLY
Alert Price: $67.61
High Price: $73.56
Results: 9% in 12 Days

Past results are not indicative of future profits. This table is accurate, though not every trade is represented.

jb-vertical


Trading Lessons

Mainstream Financial News

Archives

UBS Initiates Vertex With Buy Rating

March 9, 2017: UBS initiates Vertex Pharmaceuticals Inc with a Buy rating and a price target of $106. UBS is launching coverage of US Biotechnology with a positive outlook buoyed by (1) a better line-up of drug launches for 2017 (Biogen’s Spinraza for SMA; Regeneron’s Dupixent for atopic dermatitis, and Incyte’s Olumiant for rheumatoid arthritis), (Read More….)

Celgene Announces Positive Results from Phase III Trial of Oral Ozanimod

February 17, 2017: Celgene announced that its phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR), compared to weekly interferon (IFN) ß-1a (Avonex).

SUNBEAM evaluated two (Read More….)

Sarepta Therapeutics Candle Over Candle On Feuerstein

February 14, 2017: Sarepta Therapeutic’s stock has formed a candle over candle reversal after Feuerstein said, “Sarepta Therapeutics is being dragged down unfairly into the price-gouging muck by Marathon Pharmaceuticals.” Source: https://www.thestreet.com/story/14001431/1/defending

January 10, 2017: Baird reiterates a Buy rating on biotechnology firm Sarepta Therapeutics and set a price target of $102. Baird named Sarepta (Read More….)

Analyst Actions and Breaking News

Overnight Analyst Actions:

Raised: None

Initiates: None

Cuts: None

Overnight Headlines By Ticker:

PLX Protalix Biotherapeutics Inc

12/27 07:30 Receives confirmation of order for over $24M of alfataliglicerase to treat gaucher patients in Brazil

PTLA Portola Pharmaceuticals

12/27 07:49 Price Target raised to $29 from $20 at Credit Suisse, reiterates (Read More….)

Heavy Call Activity Detected In HD Supply

December 21, 2016: Seeing heavy call activity in HD Supply, 1,955 February $45 calls trade at $1.25. This heavier call activity comes a day after reports circulating that HD Supply has hired an adviser to gauge takeover interest on pressure from Jana.

December 20, 2016: Industrial equipment wholesale company HD Supply has reportedly hired an (Read More….)

Analyst Actions and Breaking News

Overnight Analyst Actions:

Raised:

REGN Outperform Credit Suisse First Boston TECK Outperform Macquarie

Initiates:

TECK Buy MKM Partners

Cuts:

AMGN Neutral Credit Suisse First Boston

Overnight Headlines By Ticker:

AMGN   Amgen Inc

12/20   08:21   Credit Suisse Cuts AMGN to Neutral from Outperform, price target: $180

12/19 (Read More….)

Sell Disney For an 11% Profit

May 15, 2016: Walt Disney Co “Captain America: Civil War” remained the top film at the N America box office with $72.6 million in sales… (Read More….)

Terrifying US Pension Fund Charts

Pension funds in the US could be close to a collapse. There is an estimated $1.9 trillion shortfall in U.S. state and local pension funds because of low-interest rates and a sideways US stock market. Even stocks falling overseas is a problem for pension funds.

Credit Suisse published the chilling chart below on the funding (Read More….)

Kinross Gold Corporation Strike Ends at Tasiast Mine

June 13, 2016: Strike ends at Kinoss Gold Corporation’s Tasiast Mine. The strike was settled quickly and so it is not expected to impact annual guidance. The strike by unionized employees at its Tasiast mine that began on May 24, 2016 has ended. Striking employees began returning to work on June 11, 2016 (Read More….)

Massive Layoffs In Retail Sector Bad News For Economy

Ralph Lauren was the latest big brand name consumer company to announce layoffs, saying on Tuesday that it was looking to cut about 1,200 jobs or 8% of its full-time work force.

Macy’s announced in January of 2016 that it would cut over 4,000 jobs and close 36 stores because of a poor (Read More….)